Copyright
©The Author(s) 2021.
World J Gastrointest Surg. Jul 27, 2021; 13(7): 689-701
Published online Jul 27, 2021. doi: 10.4240/wjgs.v13.i7.689
Published online Jul 27, 2021. doi: 10.4240/wjgs.v13.i7.689
Progression-free survival | 1P value | Overall survival | 1P value | ||||
No progression | Progression | Survival | Death | ||||
(n = 1388) (%) | (n = 308) (%) | (n = 1494) (%) | (n = 202) (%) | ||||
Age (yr) (mean ± SD) | 58.61 ± 11.71 | 58.48 ± 12.64 | 0.861 | 58.64 ± 11.75 | 58.19 ± 12.81 | 0.618 | |
Sex | Male | 821 (59.15) | 195 (63.31) | 0.199 | 880 (58.90) | 136 (67.33) | 0.022 |
Female | 567 (40.85) | 113 (36.69) | 614 (41.10) | 66 (32.67) | |||
Tumor location | Colon | 801 (57.71) | 178 (57.79) | 0.999 | 861 (57.63) | 118 (58.42) | 0.880 |
Rectum | 587 (42.29) | 130 (42.21) | 633 (42.37) | 84 (41.58) | |||
TNM stage | I | 216 (15.56) | 7 (2.27) | < 0.001 | 219 (14.66) | 4 (1.98) | < 0.001 |
II | 522 (37.61) | 51 (16.56) | 536 (35.88) | 37 (18.32) | |||
III | 561 (40.42) | 93 (30.19) | 570 (38.15) | 84 (41.58) | |||
IV | 89 (6.41) | 157 (50.97) | 169 (11.31) | 77 (38.12) | |||
Tumor size (cm) | d < 2 | 61 (4.39) | 12 (3.90) | 0.863 | 67 (4.48) | 6 (2.97) | 0.246 |
2 ≤ d < 5 | 886 (63.83) | 201 (65.26) | 964 (64.52) | 123 (60.89) | |||
d > 5 | 441 (31.77) | 95 (30.84) | 463 (31.00) | 73 (36.14) | |||
Differentiation | Low | 186 (13.40) | 36 (11.69) | 0.586 | 192 (12.85) | 30 (14.85) | 0.648 |
Medium | 1104 (79.54) | 253 (82.14) | 1197 (80.12) | 160 (79.21) | |||
High | 98 (7.06) | 19 (6.17) | 105 (7.03) | 12 (5.94) | |||
Circumferential margin | No | 1372 (98.85) | 301 (97.73) | 0.167 | 1477 (98.86) | 196 (97.03) | 0.047 |
Yes | 16 (1.15) | 7 (2.27) | 17 (1.14) | 6 (2.97) | |||
Vascular tumor thrombus | No | 1111 (80.04) | 218 (70.78) | 0.001 | 1180 (78.98) | 149 (73.76) | 0.101 |
Yes | 277 (19.96) | 90 (29.22) | 314 (21.02) | 53 (26.24) | |||
Nerve invasion | No | 1098 (79.11) | 228 (74.03) | 0.057 | 1177 (78.78) | 149 (73.76) | 0.122 |
Yes | 290 (20.89) | 80 (25.97) | 317 (21.22) | 53 (26.24) | |||
Chemotherapy | No | 606 (43.66) | 87 (28.25) | < 0.001 | 603 (40.36) | 90 (44.55) | 0.254 |
Yes | 782 (56.34) | 221 (71.75) | 891 (59.64) | 112 (55.45) | |||
Radiotherapy | No | 1315 (94.74) | 275 (89.29) | 0.001 | 1400 (93.71) | 190 (94.06) | 0.999 |
Yes | 73 (5.26) | 33 (10.71) | 94 (6.29) | 12 (5.94) | |||
ApoA1 (G/L) | 1.22 ± 0.25 | 1.12 ± 0.27 | < 0.001 | 1.20 ± 0.25 | 1.12 ± 0.28 | 0.010 | |
ApoB (G/L) | 0.94 ± 0.23 | 0.91 ± 0.24 | 0.170 | 0.93 ± 0.23 | 0.92 ± 0.25 | 0.628 | |
HDL-C (mmol/L) | 1.22 ± 0.33 | 1.20 ± 0.34 | 0.208 | 1.22 ± 0.33 | 1.20 ± 0.37 | 0.440 | |
LDL-C (mmol/L) | 2.62 ± 0.75 | 2.60 ± 0.84 | 0.807 | 2.61 ± 0.75 | 2.64 ± 0.90 | 0.664 |
- Citation: Gu JN, Yao S, Cao YH, Deng SH, Mao FW, Jiang HY, He YT, Li XY, Ke SQ, Li HL, Li H, Liu XH, Liu HL, Wang JL, Wu K, Liu L, Cai KL. Novel parameter based on lipid indicators ratio improves prognostic value of plasma lipid levels in resectable colorectal cancer patients. World J Gastrointest Surg 2021; 13(7): 689-701
- URL: https://www.wjgnet.com/1948-9366/full/v13/i7/689.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v13.i7.689